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Abstract
Background: Passive transfer of antibodies not only provides immediate short-term protection against disease, but also can
be exploited as a therapeutic tool. However, the ‘humanization’ of murine monoclonal antibodies (mAbs) is a time-
consuming and expensive process that has the inherent drawback of potentially altering antigenic specificity and/or affinity.
The immortalization of human B cells represents an alternative for obtaining human mAbs, but relies on the availability of
biological samples from vaccinated individuals or convalescent patients. In this work we describe a novel approach to
generate fully human mAbs by combining a humanized mouse model with a new B cell immortalization technique.
Methodology/Principal Findings: After transplantation with CD34
+CD38
2 human hematopoietic progenitor cells, BALB/c
Rag2
2/2IL-2Rcc
2/2 mice acquire a human immune system and harbor B cells with a diverse IgM repertoire. ‘‘Human
Immune System’’ mice were then immunized with two commercial vaccine antigens, tetanus toxoid and hepatitis B surface
antigen. Sorted human CD19
+CD27
+ B cells were retrovirally transduced with the human B cell lymphoma (BCL)-6 and BCL-
XL genes, and subsequently cultured in the presence of CD40-ligand and IL-21. This procedure allows generating stable B
cell receptor-positive B cells that secrete immunoglobulins. We recovered stable B cell clones that produced IgM specific for
tetanus toxoid and the hepatitis B surface antigen, respectively.
Conclusion/Significance: This work provides the proof-of-concept for the usefulness of this novel method based on the
immunization of humanized mice for the rapid generation of human mAbs against a wide range of antigens.
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Introduction
Hyper-immune sera containing polyclonal immunoglobulins
(Igs) have been widely used in both therapeutic and prophylactic
clinical settings [1]. However, the use of polyclonal sera was
associated with several problems, such as the stimulation of allergic
reactions, low reproducibility between clinical batches and high
off-label use, which finally caused a decline in their use [2]. The
advent of technologies to make monoclonal antibodies (mAbs)
derived from animals, especially mice, has overcome many of the
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13137problems associated with the use of polyclonal sera. The
technology to make monoclonal cell lines of antibody-producing
cells by fusing antibody producing plasma cells with myeloma cells
was described for the first time in 1975 by Milstein and Kohler [3].
The therapeutic potential of mAbs was immediately recognized
and in 1980 the first mAb, OKT3, was approved for therapeutic
applications. This antibody inactivates T cells, thereby preventing
rejections of organ transplants [4]. However, because of the
animal origin of the first generation of mAbs that were used in
clinical trials, human subjects treated with these antibodies
developed vigorous immune reactions against the animal proteins,
which were thereby eliminated preventing their therapeutic
actions [5]. To overcome these problems technologies were
developed to diminish the immunogenicity of mouse antibodies
by replacing part or the complete mouse antibody backbone by its
human equivalent, first generating chimeric, and subsequently
fully humanized antibodies [6]. In a parallel approach transgenic
mice bearing the human Ig region were created to obtain fully
human antibodies following immunization. The use of these mice
obviates the elaborate molecular engineering of antibodies that is
needed to humanize antibodies generated in wild-type mice,
however, the maturation process of the mouse B cells expressing
human Igs is different from that of fully human B cells [7].
Immortalization of B cells from immune humans seems to be
the logical strategy to avoid these problems. However, the methods
to achieve this goal have showed low efficiencies, although some
progress has recently been reported [8,9]. Nevertheless, the major
disadvantage of human B cells immortalization is the need for cells
from either vaccinated individuals or patients who had recovered
from an infection. Thus, to fully exploit the Ig repertoire of human
B cells in an in vivo setting, we explored the possibility to raise
mAbs following de novo induction of human B cell responses in
mice carrying elements of the human immune system (HIS). HIS
mice are generated by engrafting immunodeficient mice with
human hematopoietic stem cells (HSC) with or without human
lymphoid tissues from fetal origin [10,11,12]. In particular, mice
deficient for the recombinase activating gene-2 (Rag2) and the
common gamma chain of the IL-2 receptor (Il2rg) on a BALB/c or
a non-obese diabetic (NOD) background are permissive for human
HSC xenografts. Inoculation of newborn mice from these strains
with human HSC of fetal or umbilical cord blood origin gives rise
to robust engraftment of a number of immune cells, including T,
B, NK and dendritic cells. In this work, we describe a convenient
approach to generate fully human mAbs based on the immuni-
zation of BALB/c Rag2
2/2IL-2Rcc
2/2 engrafted with human
CD34
+CD38
2 HSC [13,14]. To this end, HIS mice were
immunized with commercial vaccines against hepatitis B virus
(HBV) and tetanus. Following immunization, human CD19
+ B
cells were sorted based on surface CD27 expression, as a marker of
memory phenotype, and the isotype of surface Igs. The sorted B
cell populations were immortalized in vitro by retroviral transduc-
tion with human B cell lymphoma (BCL)-6 and BCL-XL genes and
antigen-specific B cell clones were established and characterized.
The obtained results provided the proof-of-concept for the
usefulness of this generic approach based on HIS mice combined
with immortalization of human B cells for the rapid and
inexpensive development of human mAbs against a wide range
of antigens.
Materials and Methods
Ethics statement
The use of fetal liver tissue obtained from elective abortions with
gestational age ranging from 14 to 20 weeks was approved by the
Medical Ethical Committee of the AMC-UvA and was contingent
on informed written consent.
Generation of HIS-mice
BALB/c Rag2
2/2IL-2Rcc
2/2 mice were bred and maintained
in individual ventilated cages, and fed with autoclaved food and
water. HIS mice were generated as previously described
[13,14,15,16], with the approval of the Animal Ethical Committee
of the AMC-UvA (permit number DHL-100970). In brief, human
fetal livers were obtained from elective abortions with gestational
age ranging from 14 to 20 weeks. Magnetic enrichment of CD34
+
cells (.98% pure) was performed by using the CD34 Progenitor
Cell Isolation kit (Miltenyi Biotech), after preparation of single cell
suspensions and isolation of mononuclear cells by density gradient
centrifugation over Lymphoprep (Axis Shield). Finally, newborn
(,5 days old) sub-lethally irradiated (3.5 Gy) BALB/c Rag2
2/2IL-
2Rcc
2/2 mice were injected via intra-hepatic route with 5–10610
4
sorted CD34
+CD38
2 human fetal liver hematopoietic stem cells in
30 ml. All manipulations of HIS mice were performed under
laminar flow. Cell suspensions were prepared in RPMI medium
supplemented with 2% fetal calf serum (FCS).
BCR VH and CDR3 immunoscope analysis
Twelve to sixteen weeks after CD34
+CD38
2 HSC engraftment,
HIS mice were killed and single cell suspensions of splenocytes
were prepared. Red cells lysis was performed in 1 ml of red cell
lysis buffer (Sigma) for 10 min. Splenocytes were washed,
resuspended in 600 ml of RLT lysis buffer (Qiagen) and
homogenized by passing through a 21-gauge needle several times
using RNase free syringes. RNA was prepared using RNeasy mini
kits (Qiagen) according to manufactures instructions. BCR VH
immunoscope was performed as previously described [17]. Briefly,
cDNA was prepared and real-time PCR performed by combining
primers for the different VH chains (VH1-7) and specific
fluorochrome-labeled probes against the different constant regions
(CHm,C Ha and CHc). An additional four PCR cycles ‘run-off
reactions’ were then performed on the PCR products using
fluorescent primers specific for the constant regions (Fcm,F c a and
Fcc). Products were gel separated to determine CDR3 lengths.
Analysis of six individual HIS-mice containing greater than 30%
human chimerism in the spleen was performed. The number of
human CD19
+ B cells in chimeric spleens ranged from 5–12610
6.
Immunization protocol and sample collection
Eight weeks after HSC transplantation, blood was taken from
HIS mice to verify the level of engraftment by flow cytometry, as
described elsewhere [18]. HIS mice with a good level of human
reconstitution (.20% hCD45
+ cells) were immunized by intra-
muscular route (biceps femoris) using a 29G needle, three times on
weeks 14, 16 and 18 with either 100 ml of the HBV vaccine
(Engerix-B, GlaxoSmithKline) or 50 ml of tetanus toxoid (TT)
containing vaccine (Tetanus vaccine, The Netherlands Vaccine
Institute). These amounts correspond to 1/10 of the normal
human dose. Negative controls received the same volume of PBS
buffer. Two weeks after the last immunization, HIS mice were
exsanguinated under isofluran/oxygen narcosis. Spleens and mLN
were removed aseptically and cellular suspensions were prepared.
The BM cells were isolated from the femur and tibia.
Flow cytometry analysis and B cell sorting
Cell suspensions were labeled with FITC, PE, PerCP-Cy5.5, PE-
Cy7, APC or APC-Cy7 coupled anti-human mAb targeting the
followingcell surfacemarkers: CD1a (T6-RD1)and CD38 (CLT16)
HIS Mice to Produce Human mAb
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(HIB19), CD38 (HIT2), CD45 (2D1 and HI30), CD45RA (HI100),
CD138 (MI15), IgM (G20-127), IgD (IA6-2), IgG (G18-145) and
CCR7 (3D12) from BD Biosciences; CD27 (LT27) from AbD-
Serotec; CD27 (LG.7F9) from eBioscience. TT-specific B cells were
also occasionally stained with PE-coupled TT, kindly provided by
Dr. Andreas Radbruch (German Rheumatism Research Center,
Berlin, Germany). Dead cells were excluded based on DAPI
incorporation. All washings and reagent dilutions were done with
PBS containing 2% FCS and 0.02% NaN3. Stained cells were
analyzed with an LSR-II interfaced to a FACS-Diva software
system (BD Biosciences). Cell sorting of B cell subsets were
performed on HIS mouse BM and spleens using a FACS-Aria cell
sorter interfaced to a FACS-Diva software system (BD Biosciences).
For these experiments, all washings and reagent dilutions were done
with 2% FCS supplemented PBS without NaN3.
Retroviral transduction, culture and Ig-VH sequence
analysis of human B cell clones
The human BCL6 [19,20] and BCL-XL [21] encoding cDNAs
were further cloned in a LZRS retroviral expression vector, around
a T2A cleavage-promoting peptide sequence and upstream a
cassette containing an internal ribosome entry site (IRES) and the
gene encoding GFP. We therefore obtained a LZRS vector in the
following configuration: BCL6-T2A-BCLXL-IRES-GFP [9].
Transfection of Phoenix-GALV packaging cells and virus produc-
tion were performed as previously described [22]. Before retroviral
transduction, memoryB cellswere activated onc-irradiated (50 Gy)
mouseLcellfibroblastsstablyexpressing CD40L(CD40L-Lcells)in
the presence of 25–50 ng/ml recombinant mouse interleukin-21
(rmIL-21, R&D systems) for 36 h [19]. The B cells were washed,
mixed with retroviral supernatants in Retronectin-coated plates
(Takara), centrifuged at room temperature for 60 min at 360 g, and
subsequently incubated with the retroviruses at 37uC, 5% CO2 for
6–8 h. Transduced B cells were maintained in co-cultures using
CD40L-L cells (10
5 cells/ml) and in standard IMDM (Gibco)
culture medium supplemented with 8% fetal bovine serum (FBS;
HyClone), penicillin/streptomycin (Roche) and 25 ng/ml rmIL-21.
The analysis of human Ig-VH sequences was performed as
follows. Total RNA was isolated from approximately 5610
5
monoclonal B cells with Trizol (Invitrogen). The cDNA was
generated and subjected to PCR with primers specific to the
different VH family members. PCR products were sequenced to
determine the CDR3 region of the different clones. Sequence
analysis was performed using BigDye Terminator chemistry
(Applied Biosystems Inc.) and CodonCode Aligner software.
ELISA screening for antigen-specific B cells
The plasma harvested from HIS mice (7 days after the first and
second immunization; 10 days after the third immunization) and B
cell clone culture supernatants were screened by ELISA for the
presence of total human IgM, total human IgG and antigen-
specific antibodies. Measurement of total IgM and IgG was
performed by coating 96-well plates either with AffiniPure F(ab’)2
fragment goat anti-human IgM (Fc5m-specific, Jackson Immu-
noResearch) or AffiniPure goat anti-human IgG (Fcc fragment-
specific; Jackson ImmunoResearch). Control human serum
protein calibrator (Dako) with known IgM (0.8 mg/ml) and IgG
(10.4 mg/ml) concentrations was used as a standard to be
compared to the samples. For the detection of antigen-specific
antibodies, 96-well plates were coated either with tetanus vaccine
(Nederlands Vaccin Instituut) or Engerix B (GlaxoSmithKline)
(106 diluted in PBS) for 1 h at 37uC or overnight at 4uC.
Alternatively, Ridascreen Tetanus IgG ELISA plates (Biopharm)
were also used to screen for TT-specific antibodies. After coating,
the plates were washed in ELISA wash buffer (PBS, 0.5% Tween-
20). A PBS solution containing 4% of milk was used as a blocking
agent, before adding serial dilution of HIS mouse plasma (starting
at a dilution of 1:5) or cell culture supernatants (starting at a
dilution of 1:2). Enzyme-conjugated detection antibodies were
added at a dilution of 1:2500 for HRP-conjugated anti-IgG and a
dilution of 1:5000 for HRP-conjugated anti-IgM (both from
Jackson ImmunoResearch). Then, TMB substrate/stop solution
(Biosource) was used for the development of the ELISA assay.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 5.02 for Windows (GraphPad Software). Data were
subjected to two-tailed unpaired Student t test analysis. The
obtained p values were considered significant when p,0.05.
Results
HIS mice contain a large B cell IgM repertoire
We have generated HIS mice by transplanting human HSC into
alymphoidBALB/cRag2
2/2IL-2Rcc
2/2newbornmice(Figure1A).
As reported previously, multilineage human hematopoietic reconstitu-
tion is observed in HIS mice, which demonstrate human thymopoiesis,
B cell differentiation, NK cell and plasmacytoid dendritic cell
development, and myelopoiesis [10,13,14,15,16]. Human immune
cells accumulate in lymphoid tissues, and several B cell subsets are
observed in HIS mice (Figure 1B). We analyzed the human B cell
repertoire present in naive HIS mice by using B cell receptor (BCR)
immunoscope analysis based on quantitative PCR of Ig variable (VH)
and constant (CH) region gene segments [17]. Due to the lack of human
spleen samples, the cells isolated from HIS mouse spleens, which
contained sufficient numbers of human B cells to perform the
immunoscope analysis, were compared to control human peripheral
blood mononuclear cells (PBMC) samples, which were considered
acceptable for the purpose of the performed comparison. We observed
that IgM-expressing B cells as well as Ig isotype-switched B cells are
found in naive HIS mice (Figure 1C). The vast majority of B cells of
HIS mice expressed an IgM (97.961.0%), whereas IgG (1.861.0%)
and IgA (0.0760.04%) expressing B cells represented minor
populations. Only the frequency of IgA-expressing B cells was found
significantly higher in control human PBMC samples (p,0.0001). At
10–14 weeks post-transplantation (i.e. in steady state conditions), the
human Ig concentrations in the blood were 12268 mg/ml (IgM) and
143612 mg/ml (IgG) (Figure 1D), as previously reported [8,16]. In
comparison, the normal range for Ig concentration in healthy humans
is 400–3100 mg IgM/ml and 7200–14700 mg IgG/ml. In brief, despite
a low frequency of IgG-expressing cells, both human IgM and IgG
accumulated in the plasma of ,3m o n t h - o l dH I Sm i c et ol e v e l s
representing around 10% and 1% of adult human IgM and IgG
concentrations, respectively.
We further examined the antigen receptor repertoire diversity in
HIS mice, by determining the length of CDR3 hypervariable
regions for each Ig-VH gene family. The analysis of CDR3 length
distribution of individual HIS mouse splenocytes showed that IgM
repertoires are undistinguishable from normal human PBMC IgM
repertoires, as measured by the BCR immunoscope analysis
(Figure 1E). This observation suggests that HIS mice contain a
broad variety of naive IgM
+ B cell clones. The VH-family usage
was large and similar to control human PBMC (Table 1). The
BCR immunoscope analysis was also performed for IgG and IgA
repertoires and we observed more restricted repertoires, as
expected from B cells undergoing clonal selection and Ig class
switch recombination (Figure S1).
HIS Mice to Produce Human mAb
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13137Figure 1. Characterization of B cells in naı ¨ve HIS mice. (A) HIS mice are generated by transplanting sorted human CD34
+CD38
2 HSC-enriched
cell fraction into conditioned (3.5 Gy irradiation) newborn Rag2
2/2 IL-2Rcc
2/2 mice. After 6 to 8 weeks post-transplantation, human lymphoid and
myeloid cell subsets are found in the blood and lymphoid organs of the reconstituted animals. (B) The top panel shows the flow cytometry analysis of
human T (CD3
+) and B (CD19
+) cells found in the spleen of 8-week old HIS mice. The expression of IgM and IgD on the surface of B cells is depicted on
the low panel. (C) The relative proportion of B cells expressing an IgM, IgG or IgA BCR was determined by quantitative PCR for both control PBMC and
HIS splenocytes. Percentages represent the frequency of IgM, IgG and IgA (CHm,C Hc and CHa) containing VH PCR products out of the total VH PCR
products from each spleen. The horizontal bars indicate the mean value. (D) The graph shows the concentration of total IgM and IgG (mean values:
horizontal bars) in the plasma of 10- to 14-week old naive HIS mice. (E) The naive IgM B cell repertoire of HIS mice was evaluated on splenocytes by
performing a BCR immunoscope for each VH family. The profiles obtained with control human PBMC are also shown.
doi:10.1371/journal.pone.0013137.g001
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results in the generation of antigen-specific antibody
responses
Since HIS mice contained broad naı ¨ve B cell repertoires, we
analyzed the induction of human antigen-specific B cell responses
after immunization with commercially available human vaccines.
We designed a vaccination protocol based on repeated intra-
muscular immunizations (3 injections with 2-week intervals) of 10–
14-week old HIS mice with vaccines containing hepatitis B surface
antigen (HBsAg) or TT. Seven days after the last immunization
mice were sacrificed, the blood and the lymphoid organs were
harvested, and the phenotype and function of human cells was
analyzed.
All HIS mice showed human reconstitution (.20% hCD45
+
cells) in the blood before starting the immunization protocol,
which correlated with human engraftment in lymphoid organs.
Overall, 42% of HBsAg-vaccinated (8 out of 19 vaccinated
animals) and 40% of TT-vaccinated (6 out of 15) HIS mice
showed significant production of antigen-specific IgM antibodies,
as detected by ELISA (Figure 2A). We performed a kinetic
monitoring of antigen-specific plasma Ig levels in individual
HBsAg-vaccinated responder HIS mice and we observed that after
the first immunization antigen-specific Igs were rarely detected. In
contrast, after the second immunization antigen-specific IgM was
detected, which steadily increased after the third immunization
with approximately 25–40% of responder mice also showing an
antigen-specific IgG response (Figure 2A). This suggests that
repeated vaccination leads to enhanced antigen-specific antibody
production. The responder mice exhibited higher total IgM
(173641 mg/ml) and total IgG (4596140 mg/ml) concentrations
in their plasma, as compared to PBS-injected (IgM: 37612 mg/ml;
IgG: 191658 mg/ml) and non-responder vaccinated (IgM:
44611 mg/ml; IgG: 192667 mg/ml) animals (Figure 2B).
At the end of the immunization protocol, vaccinated animals
showed significantly higher numbers of hCD45
+ cells in all organs
(i.e. spleen, bone marrow (BM) and mesenteric lymph nodes
(mLN)) in comparison to mock-injected control mice. Responder
HIS mice exhibited higher numbers of human T and B cells in the
spleen, as well as T cells in the BM (Table 2; Table S1),
suggesting that the vaccination protocol had a positive impact on
the accumulation of human B and T cells. Moreover, the mLN
isolated from vaccinated HIS mice contained 4 to 5-fold more
hCD45
+ cells than those of control animals (Figure 2C),
suggesting that the mLN structure might play a role in eliciting
an immune response in the HIS mice.
Generation of antigen-specific monoclonal B cell lines
from vaccinated HIS mice
In humans, the CD27
+ memory B cell population contains the
majority of antigen-experienced B cells [23,24], and we reasoned
that the same should be true in vaccinated HIS mice. We therefore
cell sorted several different CD19
+CD27
+ B cell subsets from
individual HIS mice. We used two strategies to isolate the following
human B cell (CD45
+CD19
+) subsets from BM and spleens of
vaccinated HIS mice: (i) CD27
hiCD38
hi, (ii) CD27
+CD38
lo/intIgD
+,
and (iii) CD27
+CD38
lo/intIgD
2 on the one hand (Figure 3 –
Table 1. Average VH family usage for IgM in HIS (BALB-Rag/c)
mice and control human PBMC.
HIS (BALB-Rag/c) Human PBMC
VH1 0.1160.03 0.4060.07
VH2 0.0260.01 0.0560.04
VH3a 10.263.5 3.560.6
VH3b 75.164.4 79.960.1
VH4 12.563.2 11.561.7
VH5 0.0360.01 0.0760.03
VH6 0.0260.01 0.03060.002
VH7 0.000160.0002 0.0260.01
The data from HIS mice were generated with B cells isolated from the spleen of
naı ¨ve animals. The values are expressed as the relative frequency (%) of each
IgM-VH family.
doi:10.1371/journal.pone.0013137.t001
Figure 2. Vaccination of HIS mice. (A) The graph shows the titers of HBsAg-specific IgM measured by ELISA in PBS-injected and HBsAg-vaccinated
HIS mice, 10 days after the third i.m. injection. Vaccinated mice are designated as responder animals when antigen-specific antibody titers are above
the cut-off value (doted horizontal line). Responder animals with a detectable antigen-specific IgG response are indicated by the horizontal arrows.
(B) The graphs show the concentration of total IgM (top graph) and IgG (bottom graph) in the plasma of PBS-injected (open squares) or vaccinated
HIS mice (pool of HBsAg- and TT-vaccinated) at the end of the vaccination protocol (mean values: horizontal bars). The vaccinated are separated
between non-responder (- columns; open circles) and responder (+ columns; closed squares) mice. (C) The graph shows the number of human cells
(hCD45
+) harvested in mLN of PBS-injected vs. vaccinated (TT and HBsAg) HIS mice. The mLN were not detected in 43% of mock-injected mice, as
compared to 16% of vaccinated animals (symbols placed under the doted line). The animals without detectable mLN were excluded to calculate the
average number of human cells per group (horizontal bar). * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0013137.g002
HIS Mice to Produce Human mAb
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+IgM
+IgG
2 and (v)
CD27
+IgM
2IgG
+ on the other hand (Figure 3 – strategy 2, TT
vaccination). The CD27
hiCD38
hi B cell subset (i) corresponds to a
population of activated plasmablasts potentially enriched for antigen-
specific Ig producing B cells [24,25]. The CD27
+CD38
lo/intIgD
+ (ii)
and CD27
+IgM
+IgG
2 (iv) B cell subsets contain the IgM-memory B
cells [26,27], whereas CD27
+CD38
lo/intIgD
2 (iii) and CD27
+IgM
2
IgG
+ (v) B cell subsets contain the memory B cells that have
undergone class-switch recombination. Still, the frequency of
CD27
+CD38
lo/intIgD
2 (iii) B cells was higher as compared to the
frequency of CD27
+IgM
2IgG
+ (v) B cells. This apparent discrepancy
was explained by the fact that the large majority (.80%) of
CD27
+CD38
lo/intIgD
2 (iii) B cells were IgM
+ Bc e l l s .
When comparing PBS-injected HIS mice to vaccinated non-
responder and vaccinated responder animals, we did not observe any
significant difference in the frequency of CD27
+CD38
lo/intmemoryB
cells (11.561.7% [n=10], 8.260.7% [n=20] and 13.062.1%
[n=14] of total B cells, respectively) and CD27
hiCD38
hi plasmablasts
(6.462.7%, 2.560.7% and 8.662.6% of total B cells, respectively),
although the number of cells was increased for each of these
subpopulations in the vaccinated animals, as expected from the
enhanced number of total B cells (Table 2). We only observed a
Table 2. Human cell numbers measured in the spleen of vaccinated HIS mice.
Human cells (CD45
+)
Groups Total B cells (CD19
+) T cells (CD3
+)
Absolute number (610
6) Absolute number (610
6) Absolute number (610
6)
Controls (n=10) 0.7260.27 0.2560.16 0.4360.15
Vaccinated (n=34) 3.6360.75 ** 2.0360.46** 1.4560.41 n.s.
Responders (n=14) 5.6361.54 ** 3.0660.96** 2.4460.87 *
non-responders (n=20) 2.0660.45* 1.2860.35** 0.5960.20 n.s.
The data from the TT and HBsAg vaccination experiments are pooled. Values are expressed as a mean (6 S.E.M.) number of human cells, human B cells and human T
cells found in control (PBS-injected) or vaccinated animals. The vaccinated animals were further distributed between responder and non-responder animals, as
determined by antigen-specific ELISA. Statistical analysis was performed on the cell numbers harvested from vaccinated animals, as compared to the control group
(* p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0013137.t002
Figure 3. Memory B cell sorting strategies. Subsets of human B cells (CD45
+CD19
+) were sorted from BM and spleens of vaccinated HIS mice.
The strategy 1 (upper part) was used on 3 responder HBsAg-vaccinated animals and gave rise to the following B cell subsets: (i) CD27
hiCD38
hi, (ii)
CD27
+CD38
lo/intIgD
+, and (iii) CD27
+CD38
lo/intIgD
2. The strategy 2 (lower part) was used on 3 responder TT-vaccinated animals and gave rise to the
following B cell subsets: (iv) CD27
+IgM
+IgG
2, and (v) CD27
+IgM
2IgG
+. The respective frequency and name (from i to v) of each sorted B cell subsets is
indicated in the corresponding flow cytometry dot plot.
doi:10.1371/journal.pone.0013137.g003
HIS Mice to Produce Human mAb
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13137significant increase in the frequency of IgG
+ Bc e l l sw i t h i nt h e
CD27
hiCD38
hi plasmablast population of vaccinated responder HIS
mice, as compared to PBS-injected animals (13.262.7% and
4.361.8% of CD27
hiCD38
hi B cells, respectively; p=0.0311).
In order to identify, isolate and immortalize the antigen-specific
antibody-producing B cells, the aforementioned B cell subsets were
transduced immediately after cell sorting with a retroviral vector
encoding both human BCL6 and BCL-XL [9,19]. By ectopically
expressing BCL6 and BCL-XL in splenic or peripheral blood
memory B cells and culturing them with factors produced by
follicular helper T cells (CD40L and IL-21), we generated highly
proliferative, BCR positive B cell lines that secrete Igs. Since these
cells express BCL6, the differentiation of memoryB cells to terminal
plasma cells is blocked [28,29,30]. Therefore, the resulting B cells
can expand extensively in vitro for long periods of time in presence of
CD40L and IL-21, and provide a tool to generate antigen-specific
human BCR-positive, antibody-secreting B cell lines.
The number of isolated cells from spleen and antigen-specific B
cell clones that were generated with the BCL6/BCL-XL transduc-
tion approach is provided in the Table S2. Since the frequency of
antigen-specific B cell clones was unknown, we started with micro-
cell cultures ranging from 0.6 to 640 cells per well. The wells
containing antigen-specific B cells – as determined by HBsAg-
specific or TT-specific ELISA – were subsequently cultured by
limiting dilution to obtain monoclonal B cell lines. Overall, we
generated 15 anti-HBsAg IgM
+ B cell clones from 3 HIS mice
vaccinated with HBsAg, and 18 anti-TT IgM
+ B cell clones from 3
HIS mice vaccinated with TT (Table S2). The estimated
frequency of HBsAg-specific B cells (clones) in the HIS mice after
vaccination was 1/350. The IgM secretion level of the B cell
clones were in the range of 1 mg per 10
5 cells over 3 days in
culture, which was in a similar range of secretion (0.6–5 mg/10
5
cells/3 days) to what was previously reported for B cell clones
generated from human blood [9].
Characterization of antibodies produced by the B cell
clones
The IgM VH regions of the BCR of the antigen-specific IgM
+ B
cell clones were sequenced. Overall, the BCR of HBsAg-specific
and TT-specific B cell clones exhibited a VH sequence close to the
germ-line sequence, although limited frequencies of somatic
hyper-mutations were observed (Table S3 and Table S4).
Somatic hyper-mutations were occasionally detected in all
framework regions (FR) and complementary determining regions
(CDR), and most of the BCR diversity was the result of N-
additions in the CDR3 region. Based on the BCR sequence, we
observed that 12 out the 15 anti-HBsAg IgM
+ B cell clones were
unique, as well as 5 out the 18 anti-TT IgM
+ B cell clones (Table
S2, Table S3 and Table S4).
The supernatants of TT-specific B cell clones were further
tested for their capacity to recognize different antigens by ELISA.
We observed that IgM mAbs did not cross-react with unrelated
antigens (i.e., HBsAg and respiratory syncytial virus (RSV)
antigens) (Figure 4A). The TT-specific B cell clones were also
screened by flow cytometry for direct binding of the TT antigen
labeled with a fluorochrome (Figure 4B). Interestingly, three
types of clones that produced antibodies that gave a similar signal
in ELISA were detected, with high, intermediate and low binding
of the fluorescent TT antigen.
Discussion
In the present work we established a new approach to generate
fully human mAbs. We immortalized B cells from vaccinated HIS
mice by transduction with BCL6 and BCL-XL followed by
expansion in presence of IL-21 and CD40L. Antigen-specific B
cell clones were obtained that expressed the BCR on their cell
surface and secreted antigen-specific antibodies. Similarly to
methods based on the immortalization of human memory B cells
from individuals that were either vaccinated or exposed to
pathogens, our strategy exploits the antibody repertoire of human
B cells which is likely to be different from that of B cells of mice
expressing human Ig gene segments.
Naı ¨ve HIS mice display an extensive human IgM-expressing B
cell repertoire. Based on the analysis of the length of the CDR3
regions, this IgM B cell repertoire is similar to the repertoire of
healthy individuals. Thus, HIS mice have no obvious limitations
for the generation of human IgM mAbs against any possible
antigen. Upon intramuscular vaccinations with either TT or
HBsAg, approximately 40% of the HIS mice were able to mount
an antigen-specific antibody response. Human IgM-producing B
cell lines against both antigens were obtained after isolation of
memory B cells followed by ex vivo differentiation into plasmablast-
like cells. It is important to highlight that the selection of the
antigen-specific human B cell clones relied on relevant bioassays
(e.g., ELISA or neutralization test). In contrast to EBV-based
approaches, human B cell immortalization using transduction with
BCL-6 and BCL-XL preserves the expression of the BCR at the
surface and antigen-specific B cell clones can also be selected by
binding of labeled antigen to the BCR of immortalized memory B
cells (e.g. by using a labeled antigen).
Even when IgG was used as a selection criterion, we were
unable to establish antigen-specific IgG
+ human B cell clones. The
reason for this might be that T cell help in this system is
suboptimal as indicated by the absence of antigen-specific T cell
responses after vaccination (not shown). We also observed that the
BCR of the B cell clones had a close to germ-line sequence,
suggesting that also the induction of somatic hyper-mutation is
sub-optimal in HIS mice. In our hands the great majority of the
vaccinated HIS mice showed a defective formation of germinal
centers [14,16], which further explains the absence of antigen-
specific Ig-class switched B cells. So far, humanized mouse models
based on the transplantation of human HSC only – i.e. without
additional human tissues – share these limitations, and immuni-
zation strategies result in the limited generation of class-switched
antigen-specific B cell responses [14,31,32]. Similar patterns are
observed in human HSC-transplanted immunodeficient mice
infected with lymphotropic pathogens, such as HIV [33] or
EBV [34], although Dengue virus infection in HIS mice was
reported to induce an IgG response in a majority of the responder
animals [35]. It is not clear why IgG antigen-specific responses are
limited while serum IgG can accumulate efficiently, considering
the low frequency of IgG
+ B cells in HIS mice. It remains to be
determined whether this apparent discrepancy might be explained
by the conjunction of particularly effective IgG production on a
cell basis by IgG
+ B cells (which might occur in a T cell
independent manner, such as in the case of the IgG3 subclass),
long-term stability of human IgG in the HIS mouse serum as
compared to human IgM, and/or defective survival of IgG
+ B cells
under specific conditions (e.g. after antigen-specific triggering of
the BCR).
Although IgM mAbs might already be useful for some specific
applications or could be modified by Ig class swapping to obtain
IgG mAbs [36], optimized humanized mouse models with
improved B cell function are highly desirable. One reason for
the suboptimal interaction of T and B cells may be the poor
survival resulting in a high turnover of human T cells (discussed in
[10,37]), making it very likely that procedures leading to improved
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isotype switching. It was already shown that human B cells
undergoing isotype switching can be obtained in humanized mice,
provided that a human environment supporting this process is
present, e.g. in SCID mice transplanted with human fetal bones,
thymus and lymph nodes [38]. Consistent with this notion,
enhanced human peripheral T cell accumulation was observed in
NOD/SCID mice transplanted with human bone marrow HSC,
fetal liver and fetal thymus tissues (referred to as BLT mice), as
compared to conventional humanized mouse systems [39].
Interestingly, BLT mice consistently generated an antigen-specific
IgG response after HIV-infection [40]. Although it is yet unknown
whether the isotype switch observed in BLT mice is truly T cell
dependent, those data might support the idea that improved T cell
homeostasis has a positive impact on B cell responses. To obtain
humanized mouse models with improved B and T cell
homeostasis, alternative strategies not relying on the transplanta-
tion of human fetal tissues – which are not necessarily easy to
access to, for ethical, legal or practical reasons – will likely be
favored in the future. The replacement of mouse genes involved in
the hematopoietic system by their human equivalent is a valuable
strategy to improve development, maintenance and/or function of
several hematopoietic cell subsets in humanized mouse models, as
shown with cytokines, such as IL-7 and Il-15 [15,21,41,42], or
MHC molecules (N.D.H and J.P.D., manuscript submitted)
[43,44]. The fact that the human CD47 was shown to be unable
to properly interact with the mouse SIRPa indicates that re-
introducing a functional phagocyte inhibition mechanism via the
CD47/SIRPa signaling axis is another strategy of potential
interest [45].
In conclusion, our results show using two standard vaccine
antigens the general applicability of an innovative B cell
immortalization method in combination with the HIS mouse
model to generate human mAbs. Similarly to methods based on
the immortalization of human memory B cells from vaccinated or
convalescent individuals [9], our approach exploits the broad
antibody repertoire of human B cells, overcoming the potential
limitations of conventional humanized murine mAbs such as
laboriousness or impaired biological properties, synthetic antibody
libraries that require a known target antigen, and transgenic mice
bearing the human Ig locus that have limited B cell repertoires. In
addition, our method enables to exploit experimental infection
models and immunization regimes that would be unethical or
untenable in humans. Considering the upcoming advances in HIS
Figure 4. Characterization of the generated TT-specific human B cell clones. (A) After obtaining monoclonal TT-specific B cell lines, B cell
clones were tested for cross-reactivity against unrelated antigens from HBV or RSV in an ELISA test. (B) The direct binding of phycoerythrin-labeled TT
on TT ELISA positive B cell clones was determined by flow cytometry, and 3 sub-types of clones are observed: high, intermediate and low binding
clones. Values in the histograms show the percentage of cells within the indicated gate.
doi:10.1371/journal.pone.0013137.g004
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to generate human mAbs for either diagnostic or therapeutic
purposes.
Supporting Information
Figure S1 IgG/IgA B cell repertoire in naı ¨ve HIS mice.
Similarly to Figure 1E, the naive IgG (A) and IgA (B) B cell
repertoires of HIS (BALB-Rag/c) mice were evaluated on
splenocytes by performing a BCR immunoscope for each VH
family. The profiles obtained with control human PBMC are also
shown.
Found at: doi:10.1371/journal.pone.0013137.s001 (1.61 MB TIF)
Table S1 Human cell numbers measured in the BM of
vaccinated HIS mice. Data from the TT and HBsAg vaccination
experiments are pooled, and are presented as in the Table 2.
Found at: doi:10.1371/journal.pone.0013137.s002 (0.06 MB
DOC)
Table S2 Summary of B cell origin, sorted B cell numbers and
antigen-specific B cell clone numbers. Memory B cell populations
were sorted as shown in Figure 3. Limited dilutions of B cells
transduced with BCL-6 and BCL-XL were performed with 6.4 and
0.64 cells/well. After sub-cloning of the positive wells, we
generated 15 IgM
+ anti-HBsAg mAbs, of which 13 are unique
(as determined by Ig-VH sequence, see Table S3), and 18 IgM
+
anti-TT mAbs, of which 5 are unique (see Table S4). In the case of
HBsAg vaccination, the number of screened B cells was
((192*6.4)+(96*0.64))*3=3870, which eventually suggests that
the frequency of HBsAg-specific B cells is at least 1/350 B cells.
Found at: doi:10.1371/journal.pone.0013137.s003 (0.13 MB
DOC)
Table S3 IgM VH amino-acid sequence of generated HBsAg-
specific B cell clones. The germ-line sequence is given for each VH
family, with indication of framework regions (FR) and comple-
mentary determining regions (CDR). Highlighted amino-acids
correspond to N-additions (in the CDR3 region) and somatic
hyper-mutation events, whether it results in a silent mutation
(green) or not (red). Clones with identical BCR sequences are
grouped together.
Found at: doi:10.1371/journal.pone.0013137.s004 (0.02 MB
PDF)
Table S4 IgM VH amino-acid sequence of generated TT-
specific B cell clones. Data are presented as in the Table S2.
Found at: doi:10.1371/journal.pone.0013137.s005 (0.01 MB
PDF)
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